← Back to Search

Vasodilator

Topical or Oral Minoxidil for Hair Loss from Breast Cancer Treatment

Phase < 1
Recruiting
Led By Brittany L Dulmage, MD
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Established diagnosis of breast cancer stages I-IV
Self-reporting hair loss since starting endocrine therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 12 months
Awards & highlights

Study Summary

This trial is testing whether minoxidil can help treat hair loss caused by endocrine therapy in patients with breast cancer.

Who is the study for?
This trial is for women aged 18 or older with stage I-IV breast cancer who are experiencing hair loss since starting endocrine therapy, including tamoxifen or aromatase inhibitors. It's not suitable for pregnant/nursing women, those on recent chemotherapy, with certain types of alopecia, untreated thyroid/iron issues, prior minoxidil use, or a known sensitivity to it.Check my eligibility
What is being tested?
The study is testing whether topical or oral Minoxidil can help treat hair loss caused by endocrine therapy in breast cancer patients. The trial includes questionnaires and quality-of-life assessments to evaluate the effectiveness and side effects of the treatment.See study design
What are the potential side effects?
Minoxidil may cause scalp irritation when applied topically and could potentially lead to unwanted facial/body hair growth. Oral Minoxidil might result in systemic side effects like changes in blood pressure or heart rate.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with breast cancer at any stage.
Select...
I have experienced hair loss since starting hormone therapy.
Select...
I am currently on hormone therapy for my cancer.
Select...
I am a woman aged 18 or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of days assigned medication was taken/applied
Secondary outcome measures
CADS score emotional
CADS score physical
Change in hair density
+3 more

Side effects data

From 2015 Phase 2 trial • 21 Patients • NCT00876200
56%
Hypertrichosis
11%
Strabismus correction
100%
80%
60%
40%
20%
0%
Study treatment Arm
Minoxidil
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm II (orally minoxidil)Experimental Treatment3 Interventions
Patients receive minoxidil PO QD for up to 12 months in the absence of disease progression or unacceptable toxicity.
Group II: Arm I (topical minoxidil)Active Control3 Interventions
Patients apply minoxidil foam topically to affected areas of the scalp QD for up to 12 months in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Minoxidil
FDA approved

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
320 Previous Clinical Trials
290,117 Total Patients Enrolled
Brittany L Dulmage, MDPrincipal InvestigatorOhio State University Comprehensive Cancer Center

Media Library

Minoxidil (Vasodilator) Clinical Trial Eligibility Overview. Trial Name: NCT05417308 — Phase < 1
Hair Loss Research Study Groups: Arm I (topical minoxidil), Arm II (orally minoxidil)
Hair Loss Clinical Trial 2023: Minoxidil Highlights & Side Effects. Trial Name: NCT05417308 — Phase < 1
Minoxidil (Vasodilator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05417308 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any openings presently in this clinical trial?

"As per clinicaltrials.gov, this particular medical study is not presently enrolling patients. The trial first surfaced on the 1st of August 2022 and was last updated 8th June 2022. Although it's inactive at present, there are currently 2370 other trials actively recruiting individuals for their research."

Answered by AI

Who else is applying?

What state do they live in?
Ohio
What site did they apply to?
Ohio State University Comprehensive Cancer Center
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer
Brittany Dulmage 2023. "Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05417308.
All > Androgenetic Alopecia > Alopecia Areata
~24 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top